MittalPQuattrocchiGTohidi-EsfahaniI, et al. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke2023; 18: 383–391.
2.
ChenHYLeeWKChangR, et al. Immune thrombocytopenia and risk of stroke: evidence from a nationwide population-based cohort study. Int J Stroke2022; 18: 408–415.
3.
MicieliASinghNJahnB, et al. Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: a Canadian perspective. Int J Stroke2022; 18: 416–425.
4.
WangYMengXWangA, et al.; CHANCE-2 Investigators. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med2021; 385: 2520–2530.
5.
ToyodaKUchiyamaSYamaguchiT, et al.; CSPS.com Trial Investigators. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol2019; 18: 539–548.
6.
UchiyamaSToyodaKOmaeK, et al. Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis. J Am Heart Assoc2021; 10: e022575.
7.
UchiyamaSToyodaKOkamuraS, et al. Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: a subgroup analysis of the CSPS.com trial. Int J Stroke2022; 18: 426–432.
8.
NishiyamaYKimuraKOtsukaT, et al.; CSPS.com Trial Investigators. Dual antiplatelet therapy with cilostazol for secondary prevention in lacunar stroke: subanalysis of the CSPS.com Trial. Stroke2023; 54: 697–705.
9.
McHutchisonCBlairGWAppletonJP, et al. Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis. Stroke2020; 51: 2374–2385.
10.
NogueiraRGAbdalkaderMQureshiMM, et al. Global impact of COVID-19 on stroke care. Int J Stroke2021; 16: 573–584.
11.
PandianJDPanagosPDSebastianIA, et al. Maintaining stroke care during the COVID-19 pandemic in lower- and middle-income countries: World Stroke Organization Position Statement endorsed by American Stroke Association and American Heart Association. Int J Stroke2022; 17: 9–17.
12.
SouthKMcCullochLMcCollBW, et al. Preceding infection and risk of stroke: an old concept revived by the COVID-19 pandemic. Int J Stroke2020; 15: 722–732.
13.
NannoniSde GrootRBellS, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke2021; 16: 137–149.
14.
QureshiAIBaskettWIHuangW, et al. New cardiovascular events in the convalescent period among survivors of SARS-CoV-2 infection. Int J Stroke2022; 18: 437–444.
15.
Mayer-SuessLHeidbrederAKiechlS, et al. Decline in spontaneous cervical artery dissection incidence during COVID-19 public health measures: evidence for a role of upper respiratory infections in pathogenesis. Int J Stroke2023; 18: 433–436.
16.
LiWSeoJKokkinidisDG, et al. Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: an updated systematic review and meta-analysis of randomized clinical trials. Int J Stroke2022; 18: 392–399.
